Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jichun Gu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5069410392. Sources: OpenAlex.

Their work

Papers
20 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 5 papers · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 20

  1. Extracellular vesicles from chemotherapy-induced senescent tumor cells reprogram hepatic phospholipid metabolism to promote pancreatic cancer liver metastasis. Co-author DOI 10.1186/s13046-026-03741-3↗
  2. ITGA3 promotes pancreatic cancer progression through HIF1α- and c-Myc-driven glycolysis in a collagen I-dependent autocrine manner. Co-author DOI 10.1038/s41417-024-00864-7↗
  3. Integrating plasma protein-centric multi-omics to identify potential therapeutic targets for pancreatic cancer. Co-author DOI 10.1186/s12967-024-05363-9↗
  4. Ubiquitin-specific protease 7 maintains c-Myc stability to support pancreatic cancer glycolysis and tumor growth. Co-author DOI 10.1186/s12967-024-05962-6↗
  5. High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway. Co-author DOI 10.1155/2022/3243647↗
  6. The expression and survival significance of sodium glucose transporters in pancreatic cancer. First author DOI 10.1186/s12885-021-09060-4↗
  7. The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular. Co-author DOI 10.3389/fcell.2022.844028↗
  8. Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in … Co-author DOI 10.3389/fsurg.2022.890412↗
  9. CDCA8/SNAI2 Complex Activates CD44 to Promote Proliferation and Invasion of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14215434↗
  10. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer. Co-author DOI 10.1002/path.5588↗
  11. The Expression and Survival Significance of Glucose Transporter-1 in Pancreatic Cancer: Meta-Analysis, Bioinformatics Analysis and Retrospective Study. First author DOI 10.1080/07357907.2021.1950755↗
  12. WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41416-020-0929-0↗
  13. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. First author DOI 10.1042/bsr20200401↗
  14. Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment. Co-author DOI 10.7150/jca.43087↗
  15. Pancreatoduodenectomy with portal vein resection favors the survival time of patients with pancreatic ductal adenocarcinoma: A propensity score matching analys… Co-author DOI 10.3892/ol.2019.10822↗
  16. Stroma - A Double-Edged Sword in Pancreatic Cancer: A Lesson From Targeting Stroma in Pancreatic Cancer With Hedgehog Signaling Inhibitors. Co-author DOI 10.1097/mpa.0000000000001023↗
  17. Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer. First author DOI 10.3892/ol.2018.8041↗
  18. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. First author DOI 10.1016/j.ijsu.2017.10.066↗
  19. Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein invo… First author DOI 10.18632/oncotarget.20847↗
  20. Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases. Co-author DOI 10.2147/ijn.s131295↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Deliang Fu · 14 shared papers, 2017–2024 · strength 1.92
  2. Ji Li · 10 shared papers, 2018–2022 · strength 1.35
  3. Chen Jin · 10 shared papers, 2017–2024 · strength 1.21
  4. Jiali Du · 7 shared papers, 2020–2022 · strength 1.10
  5. Baian Tao · 5 shared papers, 2022–2026 · strength 0.94
  6. Junyuan Deng · 6 shared papers, 2021–2022 · strength 0.91
  7. Lei Kong · 6 shared papers, 2021–2022 · strength 0.91
  8. Hengchao Li · 6 shared papers, 2017–2024 · strength 0.86
  9. Ji Li · 4 shared papers, 2017–2024 · strength 0.53
  10. Yishen Mao · 3 shared papers, 2018–2024 · strength 0.41
  11. Lie Yao · 4 shared papers, 2017–2020 · strength 0.35
  12. Deliang Fu · 3 shared papers, 2017–2022 · strength 0.32
  13. Shu‐Heng Jiang · 2 shared papers, 2020–2024 · strength 0.31
  14. Deliang Fu · 1 shared paper, 2026 · strength 0.27
  15. Yongjian Jiang · 3 shared papers, 2017–2020 · strength 0.26
  16. Hexige Saiyin · 2 shared papers, 2018–2021 · strength 0.26
  17. Rong-Kun Li · 1 shared paper, 2025 · strength 0.25
  18. H Li · 1 shared paper, 2025 · strength 0.25
  19. Chunhua Dai · 1 shared paper, 2025 · strength 0.25
  20. Qian Ji · 1 shared paper, 2025 · strength 0.25
  21. Dejun Liu · 1 shared paper, 2025 · strength 0.25
  22. Rongkun Li · 1 shared paper, 2024 · strength 0.23
  23. Xi Xiao · 1 shared paper, 2024 · strength 0.23
  24. Siyu Zhou · 1 shared paper, 2024 · strength 0.21
  25. Zhibo Xie · 2 shared papers, 2017–2019 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.